Stonebridge Financial Group LLC bought a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 40,080 shares of the conglomerate's stock, valued at approximately $8,880,000.
A number of other hedge funds have also recently made changes to their positions in DHR. EP Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter worth about $3,807,000. Puzo Michael J purchased a new stake in Danaher in the second quarter worth approximately $8,624,000. Madison Asset Management LLC purchased a new stake in Danaher during the second quarter valued at $85,451,000. First Nebraska Trust Co purchased a new stake in shares of Danaher during the 2nd quarter valued at about $14,106,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Danaher during the second quarter valued at approximately $11,800,000. 79.05% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the company. Guggenheim lifted their price objective on Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Wells Fargo & Company lowered their price objective on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 22nd. The Goldman Sachs Group lifted their target price on Danaher from $210.00 to $250.00 and gave the stock a "buy" rating in a report on Monday, September 21st. Finally, TD Cowen cut their price target on shares of Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $232.50.
Get Our Latest Research Report on Danaher
Danaher Stock Down 4.5%
Danaher stock traded down $10.08 during midday trading on Thursday, hitting $211.47. 5,302,533 shares of the company's stock were exchanged, compared to its average volume of 4,477,097. The company has a market cap of $148.66 billion, a PE ratio of 37.56, a P/E/G ratio of 2.82 and a beta of 0.78. The firm has a 50-day moving average of $208.38 and a two-hundred day moving average of $193.37. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. As a group, analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.
Danaher Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. Danaher's dividend payout ratio is presently 28.42%.
About Danaher
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.
The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.
Further Reading
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.